ArticleFEBS letters2012
A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
Article in FEBS letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Voltage-Gated KMarine drugs · 2024Review
- Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver.PloS one · 2023Article
- Absolute Structure Determination and Kv1.5 Ion Channel Inhibition Activities of New Debromoaplysiatoxin Analogues.Marine drugs · 2021Article
- Proteomic Analysis of the Venom of JellyfishesMarine drugs · 2020Article
- Marine Toxins Targeting Kv1 Channels: Pharmacological Tools and Therapeutic Scaffolds.Marine drugs · 2020Review
- Tuning Scorpion Toxin Selectivity: Switching From KFrontiers in pharmacology · 2020Article
- Identification ofToxins · 2019Article
- A Recurrent Motif: Diversity and Evolution of ShKT Domain Containing Proteins in the Vampire SnailToxins · 2019Article
- Article
- Recent Advances in Antibacterial and Antiendotoxic Peptides or Proteins from Marine Resources.Marine drugs · 2018Review
- Review
- Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.Clinical immunology (Orlando, Fla.) · 2017Article
- Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats.Scientific reports · 2017Article
- Molecular Simulations of Disulfide-Rich Venom Peptides with Ion Channels and Membranes.Molecules (Basel, Switzerland) · 2017Review
- Tissue-Specific Venom Composition and Differential Gene Expression in Sea Anemones.Genome biology and evolution · 2016Article
- Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin.Scientific reports · 2015Article
- Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.Marine drugs · 2015Article
- Conformational flexibility in the binding surface of the potassium channel blocker ShK.Chembiochem : a European journal of chemical biology · 2014Article
- Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics.Future medicinal chemistry · 2014Review
- Immunosuppressive peptides and their therapeutic applications.Drug discovery today · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
ShK, a 35-residue peptide from a sea anemone, is a potent blocker of potassium channels. Here we describe a new ShK analogue with an additional C-terminus Lys residue and amide. ShK-K-amide is a potent blocker of Kv1.3 and, in contrast to ShK and ShK-amide, is selective for Kv1.3. To understand this selectivity, we created complexes of ShK-K-amide with Kv1.3 and Kv1.1 using docking and molecular dynamics simulations, then performed umbrella sampling simulations to construct the potential of mean force of the ligand and calculate the corresponding binding free energy for the most stable configuration. The results agree well with experimental data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.